百诚医药：12月19日召开董事会会议

Group 1 - The core point of the article is that Baicheng Pharmaceutical (SZ 301096) held its fourth board meeting on December 19, 2025, to discuss the confirmation of the audit committee members and the convener [1] - For the first half of 2025, Baicheng Pharmaceutical's revenue composition is as follows: CRO business accounts for 86.22%, commercial production accounts for 10.28%, and CDMO business accounts for 3.5% [1] - As of the time of reporting, Baicheng Pharmaceutical has a market capitalization of 5.9 billion yuan [1]